REG - Avacta Group PLC - Director Appointment

AvactaAnnouncement

19/06/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230619:nRSS0820Da&default-theme=true

RNS Number : 0820D  Avacta Group PLC  19 June 2023

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon
the publication of this announcement via a Regulatory Information Service,
this inside information is now considered to be in the public domain.

 

 

19 June 2023

 

Avacta Group plc

 

("Avacta" or the "Company" and, together with its subsidiary undertakings, the
"Group")

 

 

Director Appointment

 

Avacta appoints Shaun Chilton as Non-executive Director

 

Appointment brings additional, significant commercial and corporate
development experience to the Board

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, announces that Shaun Chilton
has today joined the Board as a Non-executive Director.

 

Shaun Chilton was most recently Chief Executive Officer ("CEO") of the
formerly London-listed Clinigen Group plc ("Clinigen"), a global
pharmaceutical and pharmaceutical services platform business, which he led
through a significant growth journey. During his tenure, the company expanded
through both an organic and a buy-and-build strategy which included
successfully completing several transformational acquisitions. The Company was
eventually sold to Triton Partners for a total consideration of c.£1.3
billion in April 2022.

 

Alongside his role as the CEO of Clinigen, Shaun was Non-Executive Chairman of
C7Health, a disruptive, venture capital-backed medical technology and services
business which executed an acquisitive growth journey before successfully
being acquired by a strategic buyer in 2022.

 

Shaun has held a number of senior and executive commercial positions over more
than 30 years in companies in pharmaceutical and pharmaceutical services
industries. These include at Pfizer, Sanofi, Wolters Kluwer Health and
KnowledgePoint360 Group (now part of UDG Healthcare).

 

Dr Eliot Forster, Chairman of the Board of Avacta Group plc commented:

"Along with my fellow Directors I am delighted to welcome Shaun to the Board
of Avacta Group. He brings a wide range of highly relevant commercial
experiences from successful healthcare businesses with similar ambitions for
growth that we have in Avacta. I know Shaun will positively impact our shared
thinking and I'm excited to have him join the company."

 

Dr Alastair Smith, Chief Executive of Avacta Group plc commented:

"I am delighted that Shaun has joined the Board of Avacta Group.  He brings
deep and extensive commercial experience to further strengthen the senior
leadership of the Group as it executes its strategy across two divisions to
build a major global healthcare business working to improve people's health
and well-being through innovative oncology drugs and powerful diagnostics."

 

Shaun Chilton, Non-Executive Director of Avacta Group, commented:

"Avacta Group is building a high value, global business that is seeking to
significantly improve people's health and well-being. I am excited to leverage
my own broad experience of growing healthcare businesses and working with the
other members of the Board to help guide Avacta to meet its very significant
potential."

 

Regulatory disclosure - The following disclosures are made in accordance
with Schedule 2(g) of the AIM Rules for Companies:

 

Shaun Edward Chilton, aged 55, holds no ordinary shares or options in the
Company. Shaun Chilton's current and previous directorships are as follows:

 

 

 Current Directorships                                 Previous Directorships (last 5 years)
 Bellbrook Consulting Ltd.                             C7 Health Ltd.Clinigen Clinical Trials Ltd.

 Mustang Topco Ltd., (trading as MAP Patient Access)   Clinigen CTS Ltd.

 Mustang Midco Ltd., (trading as MAP Patient Access)   Clinigen International Holdings Ltd.

 Mustang Bidco Ltd. (trading as MAP Patient Access)    Clinigen Pharma Ltd.

                                                       Clinigen Holdings Ltd.

                                                       Clinigen GAP Ltd.

                                                       Clinigen SP Ltd.

                                                       Clinigen Healthcare Ltd.

                                                       Clinigen Ltd.

                                                       Clinigen Consulting Ltd.

                                                       IDIS Pharma Ltd.

                                                       IDIS Group Holdings Ltd.

                                                       IDIS Group Ltd.

                                                       IDIS MA Ltd.

                                                       IDIS Ltd.

                                                       IDIS GA Ltd.

                                                       Keats Healthcare Ltd.

 

Save for the disclosures above, there are no further disclosures to be made in
accordance with Rule 17 and Schedule 2(g) of the AIM Rules.

 

-Ends-

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                                Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                         www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)                               Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares   www.stifel.com (http://www.stifel.com/)
 / William Palmer-Brown

 FTI Consulting (Financial Media and IR)                                         Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw                                                        Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                                  Tel: +44 (0)7891 477 378

 Lily Jeffery                                                                    lily.jeffery@zymecommunications.com

                                                                               (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com)

 

Avacta Group plc is a life sciences company working to improve people's health
and well-being through innovative oncology drugs and powerful diagnostics.
Operating through two divisions, Diagnostics and Therapeutics, the Group's
mission is to provide professionals and consumers with solutions that improve
healthcare, fitness and well-being.

 

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is
building a wholly owned pipeline of novel Affimer(®) immunotherapies and
pre|CISION™ tumour targeted chemotherapies. This approach is designed to
address the lack of a durable response to current cancer immunotherapies
experienced by most patients and reduce the severe systemic toxicities caused
by chemotherapies. There are five programmes in the pipeline as well as
several global research collaborations and licensing partnerships. Avacta's
lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the
established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in
patients with locally advanced or metastatic selected solid tumours.

 

The Affimer(®) platform is an alternative to antibodies that has been
designed to address many of the drawbacks of antibodies which, despite their
shortcomings, currently dominate the immuno-diagnostics and
immuno-therapeutics markets.

 

The pre|CISION™ tumour targeting platform can be used to modify a
chemotherapy in order to selectively release the active drug in tumour tissue
thereby reducing the systemic exposure that causes damage to healthy tissues.
pre|CISION™ modified chemotherapies are designed to reduce the side effects
and improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro
diagnostic (IVD) solutions. The Division is growing rapidly through an M&A
strategy to deliver a global scale IVD business providing market leading
solutions for healthcare professionals and consumers to inform treatment and
monitor health and well-being. In October 2022, Avacta acquired Launch
Diagnostics which serves the hospital pathology laboratory market in the UK
and Europe. In May 2023, Avacta acquired Coris Bioconcept a Belgium based
lateral flow test developer and manufacturer adding a broad range of marketed
professional-use rapid tests into the Diagnostics Division. Avacta
Diagnostic's research and development centre in Wetherby, UK uses its
proprietary Affimer(®) platform to differentiate immunodiagnostic products to
provide marketing leading performance.

 

To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADGGDLGBBDGXI